NeuroSense Therapeutics (NRSN) News Today $0.81 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 9, 2024 | prnewswire.comNeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionJuly 1, 2024 | prnewswire.comNeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugJune 24, 2024 | investorplace.comNRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024June 24, 2024 | prnewswire.comNeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsJune 21, 2024 | prnewswire.comNeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealMay 29, 2024 | msn.comEvaxion Biotech GAAP EPS of $0.03 beats by $0.53, revenue of $0.05MMay 25, 2024 | markets.businessinsider.comBuy Rating on Neurosense Therapeutics Backed by Promising ALS Treatment ResultsMay 20, 2024 | prnewswire.comNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitMay 14, 2024 | prnewswire.comNeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningMay 7, 2024 | markets.businessinsider.comNeuroSense Reports Positive Data Analysis From PARADIGM Trial With PrimeC In ALSMay 7, 2024 | prnewswire.comNeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsMay 2, 2024 | prnewswire.comNeuroSense Announces First Quarter 2024 Business UpdateApril 22, 2024 | finance.yahoo.comNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseApril 19, 2024 | investing.comNeuroSense reports positive ALS trial results, trends in biomarkersApril 18, 2024 | prnewswire.comNeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingApril 12, 2024 | finance.yahoo.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 12, 2024 | prnewswire.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 10, 2024 | prnewswire.comNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementApril 9, 2024 | markets.businessinsider.comNeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-marketApril 9, 2024 | prnewswire.comNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsApril 7, 2024 | uk.investing.comNeuroSense reports significant ALS trial results, year-end financialsApril 5, 2024 | investorplace.comNRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023April 5, 2024 | finance.yahoo.comNeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateMarch 23, 2024 | morningstar.comNeuroSense Therapeutics Ltd NRSNFebruary 21, 2024 | finance.yahoo.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 21, 2024 | prnewswire.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 7, 2024 | finance.yahoo.comNeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleJanuary 30, 2024 | finanznachrichten.deNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 30, 2024 | finance.yahoo.comNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 9, 2024 | finance.yahoo.comNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsJanuary 4, 2024 | finance.yahoo.comNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementDecember 19, 2023 | investing.comNeurosense Therapeutics (NRSN) Earnings Dates & ReportsDecember 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)December 14, 2023 | finance.yahoo.comNeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialDecember 8, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)December 6, 2023 | finance.yahoo.comWe're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn RateDecember 5, 2023 | marketwatch.comNeuroSense Therapeutics Sees Positive Safety Data in Phase 2 Trial for ALS Treatment, Shares FallDecember 5, 2023 | markets.businessinsider.comNeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary EndpointsDecember 5, 2023 | msn.comNeuroSense ALS candidate meets key study goalsDecember 5, 2023 | finance.yahoo.comNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsDecember 4, 2023 | finance.yahoo.comNeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023November 28, 2023 | msn.comNeuroSense Therapeutics GAAP EPS of -$0.67November 28, 2023 | markets.businessinsider.comNeuroSense Therapeutics 9-Month Loss NarrowsNovember 28, 2023 | finance.yahoo.comNeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | markets.businessinsider.comNeuroSense Therapeutics Concludes Successful Type D Meeting With FDA For ALS TreatmentNovember 13, 2023 | finance.yahoo.comNeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessNovember 6, 2023 | finance.yahoo.comNeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023November 1, 2023 | finance.yahoo.comNeuroSense Therapeutics to Participate in BIO-Europe FallOctober 19, 2023 | finance.yahoo.comRenowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeCOctober 19, 2023 | marketbeat.comTrading was temporarily halted for "NRSN" at 10:10 AM with a stated reason of "LULD pause." Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. NRSN Media Mentions By Week NRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRSN News Sentiment▼0.440.61▲Average Medical News Sentiment NRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRSN Articles This Week▼21▲NRSN Articles Average Week Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KZR News Today CUE News Today DRRX News Today PMN News Today FBIO News Today AADI News Today YS News Today ACXP News Today LEXX News Today IMRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRSN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.